Healthcare [ 13/13 ] | Biotechnology [ 127/164 ]
NASDAQ | Common Stock
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas.
The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease.
The company was founded in 2014 and is based in London, the United Kingdom.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 13, 24 | -0.30 Increased by +38.78% | -0.32 Increased by +6.25% |
| Nov 13, 23 | -0.40 Increased by +4.76% | -0.31 Decreased by -29.03% |
| Aug 14, 23 | -0.38 Increased by +20.83% | -0.30 Decreased by -26.67% |
| Jun 28, 23 | -0.20 Increased by +25.93% | -0.36 Increased by +44.44% |
| Feb 13, 23 | -0.49 Decreased by -19.51% | -0.39 Decreased by -25.64% |
| Nov 14, 22 | -0.42 Decreased by -31.25% | -0.42 |
| Aug 15, 22 | -0.48 Decreased by -71.43% | -0.32 Decreased by -50.00% |
| Jun 28, 22 | -0.27 Decreased by -172.97% | -0.32 Increased by +15.62% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 37.14 M Increased by +117.80% | 5.10 B Increased by +1.42 K% | Increased by +13.72 K% Increased by +707.90% |
| Sep 30, 23 | 37.10 M Increased by +196.03% | -304.33 M Increased by +3.67% | Decreased by -820.27% Increased by +67.46% |
| Jun 30, 23 | 21.62 M Increased by +400.67% | -291.82 M Increased by +17.52% | Decreased by -1.35 K% Increased by +83.53% |
| Mar 31, 23 | 27.38 M Increased by +196.82% | -175.42 M Increased by +39.78% | Decreased by -640.79% Increased by +79.71% |
| Dec 31, 22 | 17.05 M Decreased by -29.95% | -384.90 M Decreased by -35.27% | Decreased by -2.26 K% Decreased by -93.09% |
| Sep 30, 22 | 12.53 M Decreased by -10.40% | -315.92 M Decreased by -51.53% | Decreased by -2.52 K% Decreased by -69.11% |
| Jun 30, 22 | 4.32 M Decreased by -44.16% | -353.78 M Decreased by -330.48% | Decreased by -8.19 K% Decreased by -670.96% |
| Mar 31, 22 | 9.22 M Decreased by -39.11% | -291.31 M Increased by +42.83% | Decreased by -3.16 K% Increased by +6.12% |